Releases Details
Presentations at Upcoming Virtual IR Conferences
Released : November 09, 2020 07:00
MaxCyte to Present at Two Upcoming
Virtual Healthcare Investor Conferences
Stifel 2020 Virtual Healthcare Conference
November 16-18, 2020
MaxCyte presentation: Tuesday, November 17, 10:00 a.m. to 10:30 a.m. (EST)
Jefferies Virtual London Healthcare Conference
November 17-19, 2020
MaxCyte presentation: Thursday, November 19, 1:10 p.m. to 1:40 p.m. (EST)
About MaxCyte MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in ###
Contacts:
|
|
||||||||
|
|
||||||||
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.